Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Diabetes, Obesity & Metabolism|May 17, 2024
Total and H-specific growth/differentiation factor 15 levels are unaffected by liraglutide or naltrexone/bupropion administrationSofia K Konstantinidou, Georgia Argyrakopoulou, Stamatia Simati, et al.
Endocrine Reviews|July 13, 2026
Newer and novel antidiabetic drug classes across the cardiovascular-kidney-metabolic continuumKonstantinos Stefanakis, Paschalis Karakasis, Dimitra Vasdeki, et al.
Nature Communications|October 14, 2020
Leptin alters energy intake and fat mass but not energy expenditure in lean subjectsPavlina Chrysafi, Nikolaos Perakakis, Olivia M Farr, et al.
Endocrine Reviews|July 15, 2026
MASLD and the Cardiovascular-Kidney-Liver-Metabolic syndromeAngeliki M Angelidi, Chrysoula Boutari, Michail Kokkorakis, et al.
Diabetes, Obesity & Metabolism|November 25, 2025
Effects of liraglutide treatment for 18 days on metabolic parameters, regional body composition and the myostatin-activin-follistatin-IGF-1 axis: Results from an exploratory, randomized, placebo-controlled, crossover studyValeria Gutierrez de Piñeres, Claudia S Tamayo-Torres, Arantxa Ramirez-Cisneros, et al.
Diabetes, Obesity & Metabolism|November 3, 2020
Effect of the glucagon-like peptide-1 analogue liraglutide versus placebo treatment on circulating proglucagon-derived peptides that mediate improvements in body weight, insulin secretion and action: A randomized controlled trialSun H Kim, Fahim Abbasi, Clara Nachmanoff, et al.
Metabolism: Clinical and Experimental|July 12, 2022
PCSK9 and ANGPTL3 levels correlate with hyperlipidemia in HIV-lipoatrophy, are regulated by fasting and are not affected by leptin administered in physiologic or pharmacologic dosesEirini Bouzoni, Nikolaos Perakakis, Margery A Connelly, et al.
Clinical Nutrition (Edinburgh, Scotland)|July 7, 2023
Circulating levels of all proglucagon-derived peptides are differentially regulated postprandially by obesity status and in response to high-fat meals vs. high-carbohydrate mealsKonstantinos Stefanakis, Alexander Kokkinos, Stamatia Simati, et al.
Diabetes Research and Clinical Practice|May 28, 2026
Repurposing GLP-1 receptor agonists and SGLT-2 inhibitors in neurodegeneration and metabolically at-risk populations: Myth or reality? An overview of randomized clinical trialsMichail-Angelos Mourtzos, Dimitrios Patoulias, Natalia-Maria Keklikoglou, et al.
Diabetes Research and Clinical Practice|January 22, 2026
Effects of liraglutide treatment for 35-days on total and regional fat, lean, and bone mass, and on the Myostatin-Activin-Follistatin-IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover studyValeria Gutierrez de Piñeres, Arantxa Ramirez-Cisneros, Claudia S Tamayo-Torres, et al.
Pageof 3